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 Abstract: 
 
RNA interference (RNAi)-based gene silencing is widely used in laboratories for gene function studies 
and also holds a great promise for developing treatments for diseases. However, in vivo delivery of 
RNAi therapy remains a key issue. Lentiviral vectors have been employed for stable gene transfer and 
gene therapy and therefore are expected to deliver a stable and durable RNAi therapy. But this does not 
seem to be true in some disease models. Here we showed that lentivirus delivered short-hairpin RNA 
(shRNA) against human papillomavirus (HPV) E6/E7 oncogenes were effective for only two weeks in 
cervical cancer model. However, using this vector to carry two copies of the same shRNA or two 
shRNAs targeting at two different but closely related genes (HPV E6 and VEGF) was more effective at 
silencing the gene targets and inhibiting cell or even tumor growth than their single shRNA 
counterparts. The cancer cells treated with dual shRNA were also more sensitive to chemotherapeutic 
drugs than single shRNA treated cells. These results suggest that a multi-shRNA strategy may be a 
more attractive approach for developing a RNAi therapy for this cancer.  
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Introduction: 
 
RNAi triggered by small RNA has proved to be a powerful tool for gene function studies and also 
shows great potential for the treatment of viral diseases, genetic disorders, and cancers (1-5). To date, 
several siRNA treatments have been tested in clinical trials (6-7). For cancer treatment, cervical cancer 
is an ideal model because it is highly associated (99%) with HPV infection and viral early genes, E6 
and E7, of high-risk HPV types are primarily responsible for the transformation of the epithelial cells 
and their continuous expression is essential for cancer cell survival (8-10). Therefore, these two 
oncogenes are regarded as ideal targets for developing and testing RNAi-based therapeutic treatments. 
Previously, studies, including our own, have demonstrated that silencing HPV E6/E7, with siRNA or 
shRNA, leads to cervical cancer cells undergoing apoptosis or senescence (11-14) and inhibition of 
tumor growth in vivo (14-17).  
These results suggest that RNAi therapy could be developed for cervical cancer treatment. However, 
for this treatment to become a reality a number of issues need to be addressed including achieving 
stable and durable RNAi. Previously, we showed that lentivirus-delivered shRNA triggered effective 
silencing of E6 and E7 and led to cervical cancer cell growth inhibition in vitro and in vivo (14). 
However, while lentiviral-mediated gene silencing is thought to be stable and long lasting there were 
reports on the short-lived delivery of lentiviral vector (18, 40).  
In addition to the above issue, cervical cancer cell lines CaSki and SiHa have been reported to be able 
to develop resistance to RNAi via the expression of a previously unknown 50kDa cytoplasmic protein 
that interacted with the unwound antisense strand of E7 siRNA from the RISC (21). The resistance was 
not only seen in siRNA treatment but was also seen in shRNA (22). Such resistance in cervical cancer 
cells could be an obstacle for the development of RNAi-based treatment. One potential solution to 
overcome these issues is to develop a multiple shRNA strategy or combine RNAi treatment with 
chemical-based cancer drugs (23-24). The multiple shRNA strategy has been investigated in the 
context of HIV-1 treatment and shown to successfully overcome viral escape and mutation (25-26). For 
example, Brake et al showed that HIV-1 could escape from a single shRNA attack but not from four 
shRNAs that were simultaneously expressed in a cell (27). A multiple shRNA strategy was also used to 
silence hepatitis C or B virus and superior inhibition of viral replication was observed (28-29). 
However, multiple shRNA strategy has not been well studied in cancers and not investigated for 
cervical cancer and this strategy may be used to overcome RNAi resistance in cervical cancer.  
Here we investigated the durability of lentiviral-delivered RNAi treatment as well as a multiple shRNA 
strategy in cervical cancer HeLa cells, targeting HPV 18E6E7 and VEGF, which is a well-known 
angiogenesis factor important for tumor formation and growth. We show that both shRNAs worked 
well at silencing their target genes in the dual shRNA construct. Dual shRNA therapy was more 
effective than single shRNA in gene silencing and inhibition of cell and even tumor growth.  
 
Materials and Methods: 
 
shRNA design and cloning:  
The shRNA targeting at HPV 18E6 (18E6-1) was as previously described (14). This shRNA targets at a 
common site of all three alternative spliced mRNA classes of HPV 18 and was shown to be effective at 
simultaneous knockdown of both E6 and E7 expression as they are bi-cistronically transcribed (14). 
The shRNA targeting human VEGF-A (shVEGF-2) was adopted from previous publication and was 
shown to be effective at silencing VEGF (30). For dual shRNA design, we used two simple methods: 
direct synthesis and linking method. In the first case, the two shRNA expression cassette and their 
complementary strands were synthesized as one DNA fragment (PROLIGO, Lismore, Australia) and 
annealed in the annealing buffer (100mM K-acetate, 30mM HEPES-KOH pH7.4, 2mM Mg-acetate) by 
heating to 95°C for 5 min followed by cooling to room temperature. The two cassettes were spaced by 
Bam H I site (for further cloning or restriction digesting check) and the first shRNA Xho1 site was 
replaced by the Bam H I site. For the linking method, each shRNA expression cassette and its 
complementary strand were synthesized and annealed as above. The first shRNA expression cassette 
ended with Bam H I site rather than Xho1 site and the second one started with Bam H I site rather than 
Hpa I site. The annealed two shRNA expression cassettes were linked together using the method 
previously described (31). Above annealed oligo DNA was cloned into plasmid pLentiLox3.7 (pLL3.7, 
transfer vector) as described previously (14). The insert was confirmed by both restriction enzyme 
digestion and DNA sequencing. Plasmid pLL3.7 has a self inactivating LRT (32) for the bio-safety 
consideration and also contains an eGFP gene under CMV promoter, this enables monitoring the 
infection of lentiviruses by eGFP expression. Other lentiviral packaging plasmids were as described in 
detail by Dull et al (33) and were used for third generation lentiviral vector production.  
 
LV-shRNA production  
Lentiviral production and titration were as previously described (14). Briefly, the packing plasmids and 
pLL3.7 were amplified in E. coli and purified using W/Endo-free Qiagen Maxi-Prep Kits (Promega, 
Sydney   Australia)   according   to   the   manufacturer’s   instructions.   Packing   cell   line 293T cells were 
transfected with 6.6 g pLL3.7 (-/+ insert) and 3.3 g of each packaging plasmid in 133 l 1.25M CaCl2, 
0.5ml H2O, and 0.66ml 2x HBS (140mM NaCl, 1.5mM Na2HPO4, 50mM HEPES, pH 7.05) in a T75 
flask. The viral supernatant was harvested and concentrated using Vivaspin 20ml Concentrators (100 
MW, VivaScience Sartorius Group, Sydney Australia). The lentiviral stocks were stored in small 
aliquot at -80oC for titration and cell infection.  
 
Cell transduction and flow cytometry  
HeLa cells were maintained in DMEM supplemented with 10% heat-inactivated foetal calf serum, 100 
units/ml penicillin G, 100ug/ml streptomycin sulphate and 0.29mg/ml of L-Glutamine (Gibco-
Invitrogen). For transduction, cells were plated in 6-well plates (1x105 cells /well) or in T25 flasks (2x 
105 /flask) and were cultured overnight. LV-shRNAs diluted in medium containing 8µg/ml polybrene 
were added to the cells in 0.5ml (6-well plate) or 1ml (flask) polybrene-medium for incubation for 1 
hour at 37oC. Fresh polybrene DMEM medium was added and incubation continued for 48 hours. 
Transduced HeLa cells were continuously cultured and harvested by trypsin and washed with PBS 
before resuspending in 0.5ml 1% paraformaldehyde/PBS for flow cytometry analysis using FACS 
Calibur or FACS Canto.  
 
Colony forming assay  
Transduced HeLa cells were harvested and counted. One hundred cells were seeded in each well of 12-
well plates with 1 ml complete DMEM, each group has 3 or 4 repeats. The cells were cultured for 7 
days and then fixed with 95% ethanol for 30 mins at room temperature and stained with 0.1% crystal 
violet for 5 mins. The colony was counted and the data was presented in mean of the 3 repeats.  
 
Western blotting  
Western blotting was conducted as previously described (14). HeLa cell lysates were collected after 
lentiviral transduction or at intervals of two weeks during continuous culture. Anti-HPV 18E7 
polyclonal antibody was purchased from Santa Cruz Biotechnology. Anti-human Bax polyclonal 
antibody was from Cell Signaling Technology. Anti-human  β-tubulin antibody was from Sigma.  
 
PCR and Real-time PCR 
Freshly transduced HeLa cells were harvested for total RNA and DNA extraction using TRIzol® 
reagent (Invitrogen) as instructed by the manufacturer. Reverse transcription reactions were performed 
with oligo-dT primer. The primers for RT-PCR were as following: 18E7; Forward 5’-
AAAATGAAATTCCGGTTGA-3’; Reverse 5’-GGCTGGTAAATGTTGATGAT-3’; VEGF: Forward 
5’-TCTACCTCCACCATGCCAAGT-3’;;  Reverse 5’-GATGATTCTGCCCTCCTCCTT-3’;;  Human  β-
actin:  Forward  5’-AGCCTCGCCTTTGCCGA-3’;;  Reverse:  5’-CTGGTGCCTGGGGCG-3’.  Real-time 
PCR was carried out with SYB green master mixture (Promega) using a Rotor-Gene RG-3000 (Corbett 
Research, Australia) with the following program: pre-heating 95oC 10min; then 40 cycles of 94 oC 
15sec; 58 oC 30sec; and 72 oC 30sec. The results were analyzed using Rotor-Gene6 software and 
presented as mean ± SEM of relative gene expression, which were normalized by actin expression as 
previously described (34).  
PCR was performed for pLL3.7 vector and 18s rDNA in transduced HeLa cells. The primers for 
pLL3.7   were   (Forward   5’-CAGTGCAGGGGAAAGAATAGT-3’;;   Reverse   5’-ATGGGCTATGAA 
CTAATGAC-3’)  and  human  18S  rDNA  (Forward  5’-CCA TCG AAC GTC TGC CCT A-3’;;  Reverse  
5’-TCA CCC GTG GTC ACC ATG-3’)  were   as   described   previously   (35). 18s rDNA was a single 
copy gene and was used as DNA loading control. The PCR was performed in 20 µl volume with 2.5 µl 
of reverse transcription product. PCR program was pre-heating 95oC for 5 min; the cycle of 94 oC for 
45sec; 56 oC for 1min; and 72 oC for 2 min. Twenty seven cycles were used for detecting E6/E7 mRNA 
and 40 cycles for short form mRNA detection.  
 
Cell Titer-blue assay for cell viability and drug treatment:  
Transduced HeLa cells were cultured and counted, 3 x 104 cells in 100 µl medium were seed in each 
well of 96-well plates. Each transduced cell line has 4-6 repeats. DMEM medium were used as blanks. 
The cells were cultured overnight and then 15µl CellTiter-BlueTM reagent (Promega) was added to each 
well and the cells were incubated for 30-40 minutes at 37oC. The reaction was stopped by transferring 
the supernatant to another plate and the plates were read by Taqman 7700 (AB Applied Biosystems) for 
fluorescence. For drug sensitivity assay, the transduced cells were seeded in 96-well plates as above 
and 50 µl fresh medium containing 3 times of the final concentrations (Rapamycin 20nM and SAHA 
5µM) of drugs were added to each well. The following Cell Titer-blue assay was same as above.  
 Animal experiments  
Female Rag-/- mice of 6 weeks were used in this study. Transduced HeLa cells were harvested and re-
suspended in PBS at 1x 107cells /ml. For tumor xeno-transplant model, the mice were subcutaneously 
injected (5 mice/group) with 50 µl cell suspension to the neck scruff and the tumors was monitored by 
size and were collected and weighted at day 35 after injection. The animal experiment was approved by 
the University of Queensland animal ethics committee.  
 
Data analysis  
Data was collected and expressed as mean ± S.D for each group and unpaired t-test was used to analyze 
the differences and discriminate the significant differences (two-tails, P<0.05) between two groups. 
 
Results: 
 
1. Short-lived RNAi in HeLa cells  
We have previously observed that, comparing with E7 protein reduction in week one after transduction 
with LV-shRNA, the reduction of E7 protein level at week two was moderated (14). Our first task was 
therefore to measure shRNA-mediated suppression of E7 over a longer time course to observe if stable 
and lasting gene silencing can be achieved in cervical cancer cells with the lentiviral vector. Therefore 
we analyzed E7 protein levels over a 9 week period using HeLa cells transduced with lentivirus-
delivered shRNA (targeted to HPV 18 E6 and known as 18E6-1). We have previously shown this 
shRNA to be effective at reducing E7 protein expression as E7 is expressed from the same mRNA as 
E6 (14). HPV 18E7 protein level was suppressed at week 1 but returned to baseline by week 3 (Fig 
1A). Baseline expression was then observed for the entire 2 months of monitoring. To further confirm 
the loss of shRNA suppression after week 1, we carried out colony forming assays on shRNA-treated 
cells.  It can be seen that by week three, colony forming ability was restored to control levels (Fig 1B), 
a result consistent with the levels of E7 protein (Fig 1A). A control lentiviral shRNA against another 
HPV type, HPV 16E7 (16E7-2), was used as a negative control (36); we observed no changes in E7 
protein levels during the same period. These results indicate that gene silencing mediated by the 
shRNA 18E6-1 lasted less than 3 weeks, after which the E7 protein level and cell growth ability were 
no different from non-transduced HeLa cells.  
One explanation for the loss of gene silencing is the absence of the lentiviral vector in the host cells. To 
confirm this we examined the expression of the eGFP gene, carried on the lentiviral vector, using 
FACS. We observed that the mean fluorescent intensity declined remarkably at 3 weeks in 18E6-1 
transduced cells and further declined moderately at week 5 though these cells were still eGFP positive 
compared with negative control (Fig 1C). We had previously shown that eGFP expression was 
correlated with lentiviral vector copy number and silencing efficacy (14). From this data we assumed 
that the vector was still present in the host genome and that the loss of suppression was probably 
related to the cell population with lower eGFP expression after the death of higher eGFP expressing 
cells through apoptosis (14).  
 
2. Construction of twin and dual-target shRNAs in a lentiviral vector  
Cervical cancer cells can develop resistance to RNAi triggered by synthetic siRNA (21) and our data 
above demonstrated that shRNA delivered by lentiviral was also short-lived. One strategy to overcome 
this issue is the multi-copy or multi-target approach which allows additive or even synergistic effects to 
induce rapid cell death before resistance occurs. To investigate this possibility in cervical cancer we 
designed two shRNA constructs; one contained two copies of the 18E6-1 shRNA (twin 18E6-1) and 
the other contained the 18E6-1 shRNA and a shRNA targeting human VEGF-A (dual-target shRNA). 
VEGF is an angiogenesis factor and plays an important role in tumor formation and growth, therefore 
suppression of both genes will in principle result in inhibition of HeLa cell growth and tumor formation 
and growth. Fig 2A shows the predicted RNA fold structure. Figure 2B shows the confirmation of 
inserts by restriction enzyme digestion. The inserts were further confirmed by DNA sequencing.  
 
3. Dual shRNA constructs silence their target genes more effectively than single shRNA  
To test if our dual shRNA constructs effectively silence target genes, we produced lentiviruses 
expressing each of them. HeLa cells were transduced with lentiviruses at a 2x dose, that is twice the 
dose required to give 100% transduction efficiency (14), and RNA and protein samples were collected 
for real-time RT-PCR and Western blot analysis at various times following incubation. Single copy 
vectors expressing shRNA against just 18E6-1 or VEGF were also produced and used to compare with 
the dual shRNA constructs. A 16E7-2 shRNA was used as a negative control. Both mRNA and protein 
levels of HPV 18E7 (Fig 3A and C) and VEGF (Fig 3B) expression indicated that the dual target 
shRNA construct could effectively silence their target genes. As expected, Twin 18E6-1 was more 
effective than single copy 18E6-1 shRNA at silencing E6/E7 expression (Fig 3A). Interestingly, the 
dual-target shRNA was more effective at silencing E7 and VEGF than the single shRNA constructs 
even though one would predict they expressed the same level shRNA. This result suggests an 
interaction between HPV E6/E7 and VEGF. A few studies have shown that HPV E6/E7 could regulate 
VEGF expression (37-39). However, the current result indicates that VEGF may also modulate HPV 
E7 expression.  
 
4. Dual shRNA constructs are more effective at inhibiting cancer cell growth in vitro  
To further confirm that twin 18E6-1 and dual-target shRNA have more effect on cervical cancer cell 
growth, we tested cell viability and colony forming ability of the transduced HeLa cells. Consistent 
with E7 protein level, HeLa cells transduced with twin 18E6-1 and dual-target shRNA were much less 
viable and formed fewer colonies compared with the negative controls in both assays (Fig 4). Whereas 
VEGF shRNA alone did not significantly affect HeLa cells, cells transduced with the single 18E6-1 
were significantly less viable (Fig 4 A) and formed fewer colonies (Fig 4B, C) than the control. These 
data have further proved that the dual-target shRNA has an additive or synergistic effect on target gene 
silencing.  
 
5. Dual shRNA transduced cells increase sensitivity to drug treatments  
We previously showed that HeLa cells treated with shRNA against HPV 18 E6/E7 were 4-fold more 
sensitive to chemotherapeutic drug cisplatin (13). To investigate whether dual shRNA treated HeLa 
cells would be more sensitive to anti-cancer drugs than single shRNA treated cells, we firstly chose an 
Akt pathway inhibitor rapamycin to treat the 18E6-1 and twin-18E6-1 transduced cells. The results 
showed that the increased sensitivity to the drug treatment was observed in only two-copy shRNA 
treated cells (Fig 5A). To further confirm this result, we used another anti-cancer drug in clinical trials, 
histone deacetylase inhibitor SAHA which was shown to be able to induce apoptosis in cancer cells 
(46, 47). The results showed that though single 18E6-1 transduced HeLa cells were sensitive to SAHA 
treatment, dual shRNA treated cells of both twin and two-target shRNAs were even more sensitive to 
SAHA treatment (Fig 5B). These data suggest that twin and two-target shRNA have more profound 
impact on cell survival than their single shRNA counterparts and that for developing combinational 
therapy twin or two-target shRNA should be considered first.  
 
6. Dual-target shRNA is more effective at inhibiting tumor growth in vivo and caused more 
apoptosis  
To verify our in vitro results, we carried out tumor transplant studies using RAG knockout mice. 
Transduced HeLa cells (2x dose) were subcutaneously injected to mice and tumors were collected 35 
days after injection and weighted. Compared with untreated control (HeLa) and LV-shRNA control 
16E7-2, the average tumor weights of 18E6-1, twin 18E6-1, VEGF, and dual-target shRNA groups 
were all reduced (Fig5 A). However, only the dual-target shRNA group was significantly reduced 
(P<0.05) compared with the controls. This result is consistent with in vitro data, and further confirms 
that the dual-target shRNA is more effective at not only silencing the target genes but also inhibiting 
tumor growth in vivo. To investigate if the dual target shRNA was more effective at inhibiting cell 
growth was due to apoptosis we detected Bax protein level in the transduced HeLa cells, a downstream 
component of the p53-related apoptosis pathway. The dual-target shRNA triggered more Bax 
expression (apoptosis) in the cancer cells than other single or even twin shRNAs (Fig 5B) perhaps 
explaining why the dual-target shRNA was more effective than other shRNAs in inhibiting tumor 
growth. 
 
Discussion: 
 
The lentiviral vector has been explored as a vehicle for stable and durable gene therapy in preclinical 
treatment and clinical trials (19; 20); therefore we hoped it would also produce a long-lived RNAi in 
cervical cancer cells. However, our data indicate the gene silence delivered by this vector can last only 
about two weeks. This result is consistent with a previous observation though in different cells (18). 
The reason for this seems to be related to the presence of a cell population with lower eGFP expression 
(indicating low copy number of lentiviral vector) after the death of higher eGFP expressing cells (high 
copy numbers of lentiviral vector) through apoptosis as we previously described (14). However, there 
is another possible explanation from a previous report; that the U6 promoter was not stable in 
lentivirus-transduced cells, in this case in human primary lymphocytes (40). In our lentiviral vector, the 
shRNA expression cassette was under the control of a U6 promoter. The U6 promoter can be replaced 
by the more stable H1 promoter however H1 was shown less effective at gene silencing than U6 (40). 
Another potential explanation is that the transduced HeLa cells have developed resistance to RNAi, as 
previously described in cervical cancer cells (21). Whatever the reason, the data indicates that in 
cervical cancer, lentiviral vector can only deliver a short-lived RNAi therapy of about two weeks.  
To overcome this issue of lentiviral vector, a multiple shRNA strategy was tested, an approach that has 
the added benefit of targeting multiple genes or pathways central to cancer cell maintenance. Other 
advantages of this strategy include being able to simultaneously target isotypes of a gene and using one 
vector to carry multiple copies of shRNA targeting at different sites of a gene. In the current study, we 
explored the twin copy and dual-target shRNA strategy. It is probably not surprising to observe a better 
suppression from twin 18E6-1 compared with single 18E6-1 as we previously showed that suppression 
of E7 expression was dose-dependent on the lentiviral shRNA copy numbers. Therefore, one possible 
argument will be that twin shRNA is replaced by twice transductions with the single shRNA. However, 
the vector itself can cause side effects on the cells especially when the dose is high (14). Therefore the 
multi-shRNA strategy has its advantage for clinical application.  
In addition, the data showed that targeting HPV 18E6 and VEGF-A together gave enhanced gene 
silencing of each target gene compared to single targeted shRNA suggesting additive or synergistic 
gene silencing was occurring. In vitro, the dual-target shRNA seemed almost equal to or even more 
effective than twin 18E6-1. In vivo, only the 18E6-1-VEGF group had significantly smaller tumors than 
the controls, suggesting that silencing 18E6 and E7 together with VEGF in vivo is more efficient at 
inhibiting tumor growth in vivo than the twin 18E6-1 which inhibited only E6/E7 genes. Several studies 
have shown that silencing VEGF can slow or stop blood vessels formation (angiogenesis) in different 
cancer types (30; 41; 42). A recent study also showed that silencing VEGF, hTERT, and Bcl-xl 
simultaneously was more effective at blocking human laryngeal squamous carcinoma (Hep-2) cell 
growth and suggested this was a more attractive approach for treating human cancer (43). It has been 
also shown that silencing both VEGF isotypes A and C was beneficial for inhibiting lymph node and 
lung metastases (42). These data demonstrate that a multiple shRNA strategy combining target E6/E7 
and VEGF is an attractive treatment approach for cervical cancer or other HPV related cancers.  
An interesting observation in this study was the relationship between HPV viral oncogene E6/E7 and 
angiogenesis factor VEGF. Studies have shown that HPV 16 E6 onco-protein can increase VEGF level 
in cervical cancer cells by activating its promoter (44). It is also known that expression of HPV 16 
E6/E7 in human primary keratinocytes increased the VEGF level in these cells (39). These reports 
suggest that there is a relationship between oncogene E6/E7 and angiogenesis factor VEGF with the 
former modulates the latters expression. However, in this study, we showed that silencing VEGF could 
also affect E7 expression. As far as we are aware, this has not been reported previously. This 
observation may explain why silencing both genes had significant effect on E7 expression (mRNA and 
protein levels) and cell growth in vitro or even tumor growth in vivo. Whether VEGF affects E7 
expression through a similar pathway to the E6/E7 modulation of VEGF expression is unclear and 
would be interesting to investigate further. However, this result suggests that the multiple gene 
knockdown strategy can be used as a tool to investigate the functional relationship for two or more 
genes.  
Our data proves that the dual shRNA constructs can effectively silence their target genes. These 
constructs can be easily modified to add another one or two shRNAs (two synthesized or linked shRNA 
with BamH I site) using the BamH I cloning site to make a multiple shRNA construct. However, care 
must be taken to space each shRNA expression cassette because the simple combination of the 
expression cassettes and the repeat sequence may result in reduced activity of each shRNA or even 
deletion of some shRNA (45).  
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  Titles and legends to figures: 
 
Fig 1. Short lived RNAi in HeLa cells transduced with lentiviral 18E6-1 shRNA. HeLa cells 
transduced with lentiviral shRNA 18E6-1 against HPV 18 E6 had low level of E7 protein by Western 
blot assay at week 1 (1W) after transduction (A). However, the E7 protein level came back to the level 
of HeLa cells before transduction (H) and this lasted for 9 weeks (A). No changes in the E7 level were 
observed in the negative control, HeLa cells transduced with ineffective lentiviral shRNA 16E7-2. In 
both cases, human β-tubulin (Tub) was assayed as loading controls. B represents the result of colony 
forming assay from HeLa cells transduced with 18E6-1 and the control 16E7-2 during a period of 9 
weeks. Each time point has at least three repeats. C, FACS result of eGFP expression of 18E6-1 and 
PLL transduced HeLa cells over a 5-week period. MFI: mean fluorescent intensity. The negative 
control was the HeLa cells with mock transductions. *: P<0.05.  
 
Figure 2. Dual shRNA secondary structures and the cloning result. A and B show the 
computational RNA folding images of twin 18E6-1 shRNA (A) and two-target shRNA (B). C, the 
agarose gel image showing the DNA fragment sizes of inserts in pLL3.7 after restriction enzyme 
digestion reaction (with Xba I and Not 1). 1, DNA ladders; 2, pLL3.7 plasmid alone; 3, with single 
18E6-1 shRNA insert; 4, with twin 18E6-1 shRNA insert; 5, two-target shRNA insert.  
 
Figure 3. Gene silencing efficacy of dual shRNA constructs. The real-time RT-PCR results of HPV 
18E7 (A) and human VEGF-A (B) gene expression in HeLa cells after transduction of lentiviral 
shRNAs. Each column represents at least 3 repeats. C shows the Western blotting analysis for 18E7 
protein levels in HeLa cells after transduced with LV-shRNAs. E6-1: 18E6-1shRNA; Tw: twin 18E6-1 
shRNA; E6-1VE: two-target shRNA; 16E7: 16E7-2. D is the densitometry result of C. **: P<0.01; 
***: P<0.001. 
 
Figure 4. The effect of dual lentiviral-shRNA on cell viability and cell growth. A shows the cell 
viability result of transduced HeLa cells by using the cell-titer blue assay. Each group has 4 repeats. B 
shows the colony formation of transduced HeLa cells in a 24-well plate and C shows the colony 
counting results of each group. Each treatment has at least 4 repeats. **: P<0.01; ***: P<0.001.  
 
Figure 5. Dual shRNA treated cells are more sensitive to chemotherapeutic drugs. The cell 
viability assay (Cell–titre blue assay) result (CTB counts) of HeLa cells transduced with LV-shRNA 
and treated with Akt pathway inhibitor rapamycin (A) and chemotherapeutic drugs SAHA (B). The 
bars represent four to six repeats of each group of cells treated (+) or non-treated with the drugs. *: 
P<0.05; **: P<0.01; ***: P<0.001.  
 
Figure 6. Tumor weight and apoptosis analysis of transduced HeLa cells. A shows the result of 
tumor growth (weight) after 35 days in xeno-transplant Rag-/- mouse model. Each bar represents 5 
mice. B. Western blotting result of Bax protein, one of the downstream components of p53 apoptosis 
pathway, the cell lysate samples were collected from the same sources that were used to inject the mice 
for tumor growth. 
 
 
